{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-25-000008","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.420288+00:00","generated_at":"2026-05-26T15:16:04.574116+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Supernus SPN-820 Phase 2b misses primary endpoint in treatment-resistant depression","bullets":["SPN-820 showed MADRS score change of -12.3 vs placebo -11.9 at Week 4; p=not significant.","No statistically significant improvement on any secondary endpoints versus placebo.","Safety profile consistent with prior trials; few adverse events and well-tolerated.","CEO Jack Khattar expressed disappointment; will review data with partner Navitor Pharmaceuticals.","Study enrolled ~250 adults with TRD across 40 U.S. clinical sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-25-000008","json":"https://secwatch.observer/filing/0001356576-25-000008.json","markdown":"https://secwatch.observer/filing/0001356576-25-000008.md","text":"https://secwatch.observer/filing/0001356576-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000008/0001356576-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657625000008/supn-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T15:16:04.574116+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}